Penumbra Inc. (NYSE: PEN) saw its stock surge 13.66% in pre-market trading on Wednesday, following the release of its impressive second-quarter 2025 financial results and an upward revision of its full-year revenue guidance.

The medical device company reported Q2 revenue of $339.5 million, representing a 13.4% increase from the same period last year and surpassing the analyst consensus estimate of $327.7 million. Penumbra's adjusted earnings per share came in at $0.86, beating the expected $0.82 per share. The company's performance was particularly strong in the U.S. market, with thrombectomy revenue growing by 22.6% and vascular thrombectomy embolization (VTE) revenue surging by 42% compared to the previous year.

Adding to investor optimism, Penumbra raised its full-year 2025 revenue guidance to a range of $1.355 billion to $1.370 billion, indicating an anticipated growth of 13% to 15% over 2024 revenue. The company also maintained its forecast for U.S. thrombectomy growth at 20% to 21% compared to 2024 levels. This positive outlook, combined with the strong quarterly performance, likely contributed to the significant stock price increase. Penumbra's focus on its core neurovascular and peripheral vascular franchises appears to be paying off, as the company continues to strengthen its position in the thrombectomy market.